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REVIEWRotavirus vaccines: a story of successH. Kollaritsch1, M. Kundi2, C. Giaquinto3 and M. Paulke-Korinek1
1) Institute of Speciﬁc Prophylaxis and Tropical Medicine, 2) Institute of Environmental Health, Centre for Public Health,
Medical University Vienna, Vienna, Austria and 3) Department of Women and Child Health, University of Padova, Padova, ItalyAbstractBy January 2015, rotavirus vaccination had been implemented in national vaccination programmes in 75 countries worldwide. Two live oral
rotavirus vaccines are internationally available: human, monovalent vaccine and human–bovine pentavalent reassortant vaccine. Since January
2014, another live, oral human–bovine monovalent vaccine has been available in India. After implementation of rotavirus vaccines in
childhood immunization programmes, there has been an over 90% reduction of rotavirus hospitalizations in industrialized and resource-
deprived countries. Additionally, in Latin America, signiﬁcant reduction of rotavirus-associated deaths has been recorded. Still, numerous
countries do not recommend rotavirus mass vaccination because of assumed lack of cost-effectiveness and potential risk of
intussusception, which is estimated at 1 per 50 000–70 000 doses of rotavirus vaccines. Cost-effectiveness of vaccination is affected in
some countries by high price. Inclusion of herd protection and indirect costs in calculations for cost-effectiveness results in clear beneﬁt:
costs saved by health systems due to reduced rotavirus gastroenteritis hospitalizations far exceed the costs for implementation of
rotavirus vaccination. There have been objections that high rotavirus vaccination coverage could put selective pressure on certain
rotavirus strains against which protection after vaccination is less distinct. However, data now strongly suggest that even if there might
be a relative increase of some speciﬁc genotypes after the use of rotavirus vaccines, this is not an absolute increase in incidence from
certain genotypes and does not affect the overall effectiveness of rotavirus mass vaccination, which resulted in a major decrease of
severe cases of rotavirus gastroenteritis in both industrialized and resource deprived countries.
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E-mail: maria.paulke-korinek@meduniwien.ac.atBackgroundRotavirus gastroenteritis (RVGE) is one of the leading causes
for infant hospitalization and infant death. In 2008, WHO
estimated RVGE to have caused 450 000 deaths in children <5
years of age worldwide [1]. However, two oral live vaccines
have been available internationally since 2006 to prevent RVGE:
Rotarix® (GlaxoSmithKline, Rixensart, Belgium) (RV1) is a
monovalent vaccine, which is derived from a human G1P[8]Clinical Microbiology and Infection © 2015 European Society of Cstrain. Rotateq® (Merck and Co, Whitehouse Station, NJ, USA;
Sanoﬁ Pasteur MSD, Lyon, France) (RV5) is a pentavalent vac-
cine containing ﬁve human–bovine reassortant rotavirus (RV)
strains: four are expressing human G1, G2, G3, G4 and bovine
P7[5] and one reassortant expresses P1A[8] (human) and G6
(bovine) [1]. Furthermore, a live, human–bovine reassortant
vaccine called Rotavac (Bharat Biotech International, Hyder-
abad, India), containing G9P[11] has been available in India since
January 2014 [2].
In 2009 and again in 2013, WHO recommended RV vacci-
nation for all children worldwide, especially in countries with
high numbers of diarrhoea-associated deaths [1,3,4]. In India, it
has been estimated that RV vaccines could prevent thousands of
deaths every year [5], and in Latin American countries it was
demonstrated that RV vaccines are associated with a major
reduction in childhood mortality [6–8]. By January 2015, 75Clin Microbiol Infect 2015; 21: 735–743
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
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tion in their childhood immunization programmes (Table 1) [9].
Recommendation for RV vaccination was recently issued in
Argentina, Tajikistan, the United Kingdom, Germany, New
Zealand and 18 African countries. In Asia, only the Philippines,
Tajikistan and some regions in Thailand recommend general RV
vaccination (Table 1).
Still, there are countries in Europe where RV vaccines are
not implemented in the national vaccination programmes. Ar-
guments against implementation include lack of cost-
effectiveness and RVGE being a mild disease with low
numbers of RV-associated deaths [10,11]. Furthermore, there
are concerns against RV vaccines safety, especially with regard
to intussusception. The current review discusses the effec-
tiveness of RV vaccines, their side effects, cost-effectiveness and
whether RV vaccination has an impact on circulating RV strains.
The manuscript does not aim to give a systematic review but
rather advocates for rotavirus vaccine introduction in high-
income European countries.
RV1 and RV5 are the only internationally and widely available
vaccines and therefore only these two vaccines are discussed.
There are other locally available vaccines such as Rotavac in
India, and vaccines in China and Vietnam that will not be dis-
cussed in this review.Field effectiveness and impact of rotavirus
vaccines on death and hospitalization ratesSeveral observational studies, impact studies and post-
marketing surveillance have shown the strong effect of RVTABLE 1. Rotavirus vaccination implemented in national
immunization schedules in 75 countries worldwide (as of
January 2015) according to Rota Council [9]
Europe 11 (Armenia, Austria, Belgium, Estonia, Finland,
Georgia, Germany, Luxembourg, Norway,
Moldova, United Kingdom)
Northern America 1 + 1 regional (USA, Canada (regional))
Southern America 18 (Argentina, Bolivia, Brazil, Cayman Islands,
Colombia, Dominican Republic, Ecuador,
El Salvador, Guatemala, Guyana, Haiti,
Honduras, Mexico, Nicaragua, Panama,
Paraguay, Peru, Venezuela)
Middle East 8 (Bahrain, Iraq, Israel, Qatar, Saudi Arabia,
United Arab Emirates, Uzbekistan, Yemen)
Asia 2 + 1 regional (Philippines, Tajikistan, Thailand
(regional))
Africa 29 (Angola, Botswana, Burkina Faso, Burundi,
Cameroon, Republic of Congo, Djibouti,
Eritrea, Ethiopia, The Gambia, Ghana, Kenya,
Libya, Madagascar, Malawi, Mali, Mauretania,
Morocco, Namibia, Niger, Rwanda, Senegal,
Sierra Leone, South Africa, Sudan, Tanzania,
Togo, Zambia, Zimbabwe)
Australia 6 (Australia, Fiji, Marshall Islands, Micronesia,
New Zealand, Palau)
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectvaccination campaigns in reducing the RV disease burden in
resource-deprived as well as in industrialized countries, and
even herd protection could be demonstrated from reduced
incidence of RVGE in non-vaccinated persons aged up to 20
years [8,12–16]. Studies from Panama, Brazil and Mexico
described a reduction of deaths form diarrhoea between 22%
and 50% [8]. It has been estimated that RV1 annually prevents
about 1800 diarrhoeal deaths in Mexico and Brazil [17]. In India,
it was calculated that RV vaccine (in this case Rotavac) could
prevent almost 27 000 deaths every year [5]. However, this
estimation awaits conﬁrmation after initiation of mass vaccina-
tion. Rotavirus vaccine (in this case RV1) has been assessed to
prevent deaths also in Western European countries such as
England [18] where RVGE associated mortality is very low [19].
A review summarizing RV5 vaccine-effectiveness studies and
vaccination impact studies in the USA, Australia and Europe
described an effectiveness of RV5 between 79% and 100%
depending on the study setting and coverage [12]. In Europe,
Austria was one of the ﬁrst countries implementing universal
mass vaccination for all children in 2007. Taking Austria as an
example, in 2008, the ﬁrst year after introduction of the mass
vaccination programme, incidence rates of RVGE hospitaliza-
tions were reduced by 70% in comparison to the pre-
vaccination era 2001–2006 [20]. In 2010 and 2011, RVGE
hospitalization rates remained at comparably low levels,
showing the sustained inﬂuence of the vaccination programme
on RV circulation (decrease of hospitalization rates due to
RVGE by 70% and 64%, compared with the pre-vaccination era)
[21]. Similar data have been observed in other European
countries. In Germany, in regions with high vaccination uptake
(64%), hospitalization rates due to RVGE decreased by 60%
[22]. A case–control study from Belgium (another country
where RV vaccination was introduced in 2007 and where high
coverage rates were rapidly reached) showed an effectiveness
of RV vaccination of 90% [23]. In the UK, where RV mass
vaccination was initiated in July 2013 with RV1, within 1 year
the coverage rates with the ﬁrst dose reached more than 93%
and with the second dose they were 88%. In the RV season
2013/2014, a decrease of RV laboratory reports by 67% was
observed compared with the pre-vaccination era [24].
In Austria, a decrease of case numbers was detected not only
in the group of children covered by the free mass vaccination
programme according to their age, but also in children <90 days
of age who were too young to be fully vaccinated against RVGE,
and also in children aged from 32 months to <60 months. The
latter age group consisted of children who were not vaccinated
in the mass vaccination programme because they were born
before it was initiated. This decrease in incidence in a non-
vaccinated cohort and in a partially vaccinated one suggests
some kind of herd protection [14]. This ﬁnding in non-ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 735–743
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76% and outpatient clinic visits by 81% has been described after
2 years of use of RV5 in Finland [25]. Furthermore, herd pro-
tection after wide use of RV vaccines has been reported in
Belgium [26], Australia [27] and the USA [28].
Clinical studies investigating the ﬁeld effectiveness (FE) of
RV5 showed FE of 98% against severe RVGE [29]. Similarly, FE
for RV1 was 96% in Europe [30] and 85% in Latin America [31].
In Austria, the estimated FE of RV vaccines between 2007
and 2011 depended on the assumed scenarios for children with
unknown vaccination status: if children without known vacci-
nation history were assumed to have not received any vacci-
nation against RVGE, FE was between 95% and 98%. FE was
79% to 93% when assuming that children without known
vaccination history had the same vaccination coverage rates as
children with documented vaccination history. FE was 60% to
61% under the assumption that children without known
vaccination history had the same vaccination coverage rate thatTABLE 2. Studies of RV1 and RV5 effectiveness in different setting
Vaccine type Age group/year Effectiveness Outcome
RV1 <1 year 86% Severe RVGE
<1 year 40% Severe all cause
<1 year 63% Severe RVGE
<1 year 34% Severe all cause
up to 2 years 85% Severe RVGE
up to 2 years 37% Severe all cause
up to 2 years 42% Severe RVGE
up to 2 years 18% Severe all cause
RV1 Children below
5 years, 2009–2011
84% Medically attend
RV1 8 months and older,
2007–2009
91% RVGE hospitali
RV1 2 doses 3–59 months, 2008–2011 75% RVGE
RV1 3–11 months
12 months
2008–2010
91%
90%
RVGE hospitali
RV1 Age 18–23 months,
2010–2012
57% RVGE
RV5 <1 year 87% Severe RVGE
<1 year 72% Severe all cause
<1 year 57% Severe RVGE
up to 2 years 82% Severe RVGE
up to 2 years 96% Severe all cause
up to 2 years 41% Severe RVGE
up to 2 years 15% Severe all cause
RV5 Children <4 years,
2006–2009
88% RVGE hospitaliz
RV5 <2 years, 2008 85–89% RVGE hospitaliz
RV5 Overall
6–11 months
12 months of age
83–86%
92–93%
78–84%
RVGE hospitali
RV5 8 months and older,
2007–2009
92% RVGE hospitali
RV5 Children below
5 years, 2009–2011
70% Medically attend
RV5 3 doses 2000–2006 compared
to 2007 and 2008
89–94%
62–64%
RVGE hospitali
Non-rotaviru
hospitalizatio
RV5, 3 doses 3–59 months, 2008–2011 81% RVGE
RV1 and RV5 2007–2009 89% RVGE hospitali
RV1 and RV5 2007–2011 60–98% RVGE hospitali
Abbreviations: ED, emergency department; GE, gastroenteritis; RCT, randomized controlled t
RVGE, rotavirus gastroenteritis.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiologywas present in the overall population [14,20,21]. Similar data
were reported in Australia; after three doses of RV5, vaccine
effectiveness against hospitalization due to RVGE of 90–94%
was recorded [15]. Further details are reported in Table 2.
Considering that most RVGE cases occur in the ﬁrst 3 years
of life, duration of vaccine protection is a key element for
vaccine effectiveness. In vaccinated children, hospitalization
rates for RVGE remained low in Austria after the introduction
of mass vaccination up to 3.5 years after immunization. This
suggests that children were still protected from RVGE-related
hospitalization (at least) up to the 3rd year after being vacci-
nated [21]. In the USA, it has been shown that protection
against RVGE after RV5 infection can last at minimum for 4
years and at least until the age of 2 years after RV1 vaccination
(for RV1, data were not available for a longer period of time)
[32].This is in line with data from clinical trials showing sus-
tained protection after RV vaccination for both vaccines up to 3
years after vaccination [33,34].s
Setting Reference
6 RCT; low-mortality countries [45]
GE 1 RCT; low-mortality countries
(Latin America, Finland)
[45]
2 RCT; high-mortality countries [45]
GE 1 RCT; high-mortality countries
(Malawi, South Africa)
[45]
8 RCT; low-mortality countries [45]
GE 2 RCT; low-mortality countries [45]
1 RCT; high-mortality countries
(Malawi, South Africa)
[45]
GE 1 RCT; high-mortality countries
(Malawi, South Africa)
[45]
ed RVGE Case–control Study, USA [32]
zations and ED visits Case–control study, USA [61]
Cast–control study, Spain [64]
zation Case–control study, Belgium [23]
Case–control study, South Africa [65]
3 RCT; low-mortality countries [45]
GE 1 RCT; low-mortality countries
(Finland)
[45]
2 RCT; high-mortality countries [45]
3 RCT; low-mortality countries [45]
GE 1 RCT; low-mortality countries
(Finland)
[45]
2 RCT; high-mortality countries [45]
GE 2 RCT; high-mortality countries [45]
ations and ED visits Case–control study, USA [66]
ations and ED visits Case–control study, USA [67]
zations and ED visits Case–control study, USA [68]
zations and ED visits Case–control study, USA [61]
ed RVGE Case–control study, USA [32]
zations
s acute gastroenteritis
n
Observational study, Queensland,
Australia
[15]
Cast–control study, Spain [64]
zations Case–control study, Israel [69]
zations Observational study [14], [20], [21]
rial; RV1, monovalent rotavirus vaccine; RV5, pentavalent reasserted rotavirus vaccine;
and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 735–743
TABLE 3. Overview on studies investigating the risk of intussusception after RV1 and RV5
Country Year Details Risk/incidence for intussusception Outcome Reference
Mexico 2008–2010 RV1 Relative incidence:
30 days after dose 1: 1.8 (95% CI 1.2–2.5; p
0.001)
30 days after dose 2: 1.1 (95% CI 0.8–1.5; p
0.8)
7 days after dose 1: 6.5 (95% CI 4.2–10.1;
p < 0.0001)
7 days after dose 2: 1.3 (95% CI 0.8–2.1; p
0.3)
Attributable risk 7 days after dose 1:
3–4 additional cases/100 000
infants
[70]
Australia 2007–2008 Children 1–3 months of age Relative Risk:
1–7 days after dose 1 RV1: 3.5 (95% CI
0.7–10.1)
1–21 days after dose 1 RV1: 1.5 (95% CI
0.4–3.9)
1–7 days after dose 1 RV5: 5.3 (95% CI
1.1–15.4)
1–21 days after dose 1 RV5: 3.5 (95% CI
1.3–7.6)
Elevated risk after ﬁrst dose of RV1
and RV5
[71]
USA 2006–2010 Children 4–34 weeks of age;
RV5: 786 725 doses
(309 844 ﬁrst doses)
Compared to age-matched recipients of other
vaccines
1–7 days after all RV5 doses: standardized
incidence ratio 0.92 (95% CI 0.25–2.36)
1–30 days after all RV5 doses: standardized
incidence ratio 1.01 (95% CI 0.62–1.54)
No increased risk 1–7 or 1–30 days
after vaccination
[72]
USA 2006–2012 RV5, reports from national
passive surveillance system
for adverse events after
vaccination
RV5: >47 million distributed doses
excess risk 0–6 days after RV5 (all 3 doses):
0.79 (95% CI –0.04 to 1.62)
RV1: clustering of intussusceptions 4 to 7
days after dose 1
Increased risk 3–6 days after dose 1
of RV5 and 4–7 days after dose 1
of RV1
[73]
USA 2006–2007 85 397 RV5 recipients compared
with 62 820 DTaP recipients
Relative risk 0.8 (95% CI 0.2–3.5) No association with RV5 49
Mexico,
Brazil
2008–2010 RV1: 615 cases, 2050 controls Mexico
self controlled case series analysis
incidence ratio 1–7 days after dose 1: 5.3
(95% CI 3.0–9.3)
incidence ratio 1–7 days after dose 2: 1.8
(95% CI 0.9–3.8)
case-control-analysis
odds ratio 1–7 days after dose 1: 5.8 (95%
CI 2.6–13.0)
odds ratio 1–7 days after dose 2: 1.1 (95%
CI 0.6–2.2)
Brazil
self controlled case series analysis
incidence ratio 1–7 days after dose 1: 1.1
(95% CI 0.3–3.3)
incidence ratio 1–7 days after dose 2: 2.6
(95% CI 1.3–5.2)
case-control-analysis
odds ratio 1–7 days after dose 1: 1.4 (95%
CI 0.4–4.8)
odds ratio 1–7 days after dose 2: 1.9 (95%
CI 1.1–3.4)
Incidence rate
Mexico 1/51 000
Brazil 1/68 000
[17]
USA 2008–2013 207 955 doses of RV1 and 1 301
810 doses of RV5
Relative risk:
RV1
Relative risk compared with historical
background :within 7 days after RV1 (all
doses): 8.38
RV5
Relative risk compared with historical
background within 7 days after RV5 (all
doses): 1.13 (95% CI 0.49–2.22)
RV1 compared with RV5: within 7 days
vaccination (all doses): 9.1 (95% CI
1.42–98.93)
Increased risk for RV1 but not for
RV5
[74]
USA 2004–2011 self-controlled risk-interval design
and cohort design
RV5: 507 874 dose 1
1 277 556 total doses
RV1: 53 638 dose 1, 103 098
total doses
RV5: self-controlled risk-interval design (No
signiﬁcant increase after dose 2 or 3)
attributable risk 1–21 days after dose 1: 1.5
(95% CI 0.2–3.2)
attributable risk 1–21 days after dose 2:
–0.1 (95% CI –1.8 to 1.8)
attributable risk 1–21 days after dose 3:
–0.05 (95% CI –2.3 to 2.1)
Cohort design including exposed and
unexposed person-time:
attributable risk 1–21 days after dose 1: 1.2
(95% CI 0.2–3.2)
attributable risk 1–21 days after dose 2:
–0.2 (95% CI –1.1 to 1.8)
attributable risk 1–21 days after dose 3:
–0.3 (95% CI –1.5 to 2.3)
RV1: self-controlled risk-interval design:
1–21 days after dose 1: no signiﬁcant risk: 1
intussusception in the risk interval and no
case in the control interval; attributable risk
2.4
1.5 excess cases per 100 000 ﬁrst
doses of RV5
Potential risk after RV1
[75]
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TABLE 3. Continued
Country Year Details Risk/incidence for intussusception Outcome Reference
attributable risk 1–21 days after dose 2: 3.7
(95% CI –10.0 to 19.4)
Cohort design with exposed and
unexposed person-time:
attributable risk 1–21 days after dose 1: 1.6
(95% CI –0.6 to 10.4)
attributable risk 1–21 days after dose 2: 7.3
(95% CI 0.8–22.5)
Australia 2007–2010 RV1 and RV5
306 cases, self-controlled case
series; case–controls
Relative incidence of intussusception 1–7 days
after dose 1 of RV1: 6.8 (95% CI 2.4–19.0)
Relative incidence of intussusception 1–7
days after dose 1 of RV5: 9.9 (95% CI
3.7–26.4)
Small increased risk outweighed by
beneﬁts of vaccination
[48]
Abbreviations: DTaP diphtheria, tetanus and acellular pertussis vaccine; RV1, monovalent rotavirus vaccine; RV5, pentavalent reasserted rotavirus vaccine.
CMI Kollaritsch et al. Success story of rotavirus vaccines 739Cost–beneﬁt in industrialized countriesIn a number of European countries (for example Belgium, Italy,
Ireland or the Netherlands) and various settings, cost–beneﬁt
analyses for implementation of RV vaccines have been carried
out [9,18,35–37]. Especially when calculations consider herd
protection and indirect costs, analyses predicted that costs for
RV vaccination outweigh the costs arising for the health systems
from RVGE [9]. However, the positive cost–beneﬁt ratio is
highly dependent on the costs for the vaccine, which is an
important driver of cost–beneﬁt analysis in several countries
such as Belgium, France, Finland or the Netherlands [35,36].
For example in Germany, estimates including indirect costs for
women (work absence) predicted that the price for RV vacci-
nation still must be reduced by between 62 and 66% for a
vaccination programme to become cost-effective [37]. How-
ever, the assumptions guiding the calculations may need revi-
sion in the light of emerging evidence for the effects provided
by mass vaccination.
Calculations from England and Wales predicted that severe
RVGE could be eliminated within 2 years of implemented mass
vaccination when herd effects were taken into consideration
[38]. According to Clark et al., in England RV vaccination could
save £11 million per year by preventing three RVGE deaths,
13000 RVGE hospitalizations, 27 000 emergency visits and 74
000 visits to the general practitioner’s ofﬁce [18].
In Israel, RV1 and RV5 were predicted to prevent 540–650
hospitalizations per year with an incremental cost-effectiveness
ratio per QALY (quality-adjusted life year) gained of about
$11000 for RV1 and $30 700 for RV5 [39].Cost–beneﬁt in resource-deprived countriesIn developing countries, where numerous deaths can be
averted by RV vaccines, potential beneﬁts are even moreClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologypronounced: it has been estimated that for example in
Afghanistan 32%, in India 34%, in Bangladesh 44% and in
African countries, such as Democratic Republic of Congo,
Ethiopia or Nigeria, 28% to 31% of RV-associated deaths
could be prevented by RV vaccines. For disability-adjusted
life years (DALY) gained, estimated costs per year were
between US$8 and US$87 for the countries mentioned
above [1].Safety with a focus on intussusceptionIn 1999, an earlier RV vaccine (Rotashield, Wyeth Laboratories,
Marietta, PA, USA) was withdrawn from the market in the USA
after 9 months because of an increased risk of intussusception
(adjusted odds ratio in case–control analysis 21.7; 95% CI
9.6–48.9) within 3 to 14 days after the ﬁrst dose of vaccine in
infants < 3 months of age [40,41].
The natural background incidence of intussusception varies
in different countries. A recent review including 82 studies in
different countries all over the world with data between 1978
and 2012 described an average annual incidence rate of 74
cases of intussusception per 100 000 for children <1 year of
age (range 9–328) [42]. A multi-country study in Latin
America reports an incidence of intussusception for children
aged <1 year between 3.8 (Brazil) and 105.3 (Argentina) per
100 000 subjects-years in the pre-vaccination era
(2003–2005) [43]. According to the US health insurance
claims database, incidence rate of intussusception was 0.33 per
1000 person-years in children <1 year of age between 2001
and 2005 [44].
Due to the association of intussusception and the earlier RV
vaccine in the past, large safety studies were performed both
for RV1 and RV5 before market authorization. A good safety
proﬁle for RV1 and RV5 was demonstrated in two very large
clinical trials [29–31]. A Cochrane Review summarizing safety
data from randomized clinical trials found 4565 serious adverseand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 735–743
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serious adverse events after vaccination of 78 226 children with
RV5. Even though intussusception occurred, no signiﬁcant dif-
ference was found in its frequency or any other serious adverse
event when comparing vaccine recipients with children vacci-
nated with placebo [45].
However, post-marketing surveillance indicated a small, but
increased risk of intussusception after vaccination with RV1 and
RV5. Post-licensure-surveillance in Mexico and Brazil described
a relative risk between 1.9 and 2.6 for days 1–7 after dose 2 of
RV1 [17]. Details on the risk of intussusception after RV
vaccination are listed in Table 3. A recent review described an
attributable risk of intussusception between 0.7 and 7 per
100 000 vaccinated infants for RV1 and 2.0 to 7.7 per 100 000
vaccinated infants for RV5 [46]. Still, risk–beneﬁt analysis
clearly demonstrated that beneﬁts from vaccination outweigh
the very small risk of intussusception after RV vaccination [47].
In Australia, it was estimated that RV vaccination accounted for
an additional 14 cases of intussusception while preventing more
than 6500 hospitalizations due to RVGE [48]. Based on our
meta-analysis of all studies listed in Table 3, we calculated
attributable risks of intussusception within 1 week after vacci-
nation of 5.2 additional cases (95% CI 2.4–10.1) for RV1 and
4.2 (95% CI 1.8–8.2) for RV5 after the ﬁrst dose and a risk of
3.4 (95% CI 1.5–5.8) after RV1 and 6.0 (95% CI 0.7–15.6) after
RV5 within 4 weeks after the ﬁrst dose. For RV5, there was no
signiﬁcantly elevated risk of intussusception after dose 2 or 3.
However, the second dose of RV1, still gave a slightly increased
risk of intussusception within one week after vaccination (1.2
additional cases; 95% CI 0.1–3.0) but no signiﬁcant increase
during 4 weeks after vaccination (risk 1.1; 95% CI –0.4 to 4.8).
Compared with Rotashield where the calculations for the
incidence-rate ratio of intussusception within 3 to 7 days after
vaccination after the ﬁrst dose was 58.9 (95% CI 31.7–109.6)
[41], the risk for RV1 and RV5 is very much lower.
A possible risk of Kawasaki disease was initially reported
after RV vaccination. However, large post-marketing surveil-
lance conducted in several countries such as the USA, Germany
or Austria ruled out such an association [14,20–22,49].
Extensive post-marketing surveillance in the USA described
no increased risk of Kawasaki disease, intussusception or other
diseases in 85 150 children vaccinated with RV5 [49]. In Austria,
the overall safety proﬁle of RV1 and RV5 was favourable with
1.3 to 3.6 severe adverse events per 100 000 administered
doses, including one case of Kawasaki disease and one intus-
susception (2006 to 2011) [14,20,21]. However, a possible
underestimation might occur because these ﬁgures are much
smaller than the expected numbers [14]. Investigations from
Germany did not ﬁnd an increased risk of intussusception,
either [22].Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectStrain prevalence after implementation of
RV vaccinationMainly RV of group A causes disease in humans and at least
27 G genotypes and 35 P genotypes have been described with
more than 70 G–P combinations [50,51]. Worldwide, the ﬁve
combinations occurring most frequently are G1P[8], G2P[4],
G3P[8], G4P[8] and G9P[8], but uncommon strains have also
been detected, especially in developing countries. Strain di-
versity is a result of point mutation, genetic reassortment,
genome rearrangement and interspecies transmission [50]. Due
to this variety of RV strains, concerns have been raised that RV
mass vaccination might change the distribution of circulating RV
strains, enhance the circulation of strains against which vaccines
have lower efﬁcacy, and eventually impair the effectiveness of
vaccines [52]. However, data now strongly suggest that even if
there might be a relative increase of some speciﬁc strains after
the use of RV1 or RV5, this really is a higher proportion of the
circulating genotypes, rather than an absolute increase in inci-
dence from these genotypes; this does not affect the overall
effectiveness of RV mass vaccination, which resulted in a major
decrease of severe cases of RVGE in both the industrialized and
resource-deprived countries [52,53].
However, at the moment the impact of vaccines on circu-
lating genotypes is not yet fully understood and there are
contradictory ﬁndings. Hence, monitoring of circulating geno-
types has been initiated in many countries. Studies in the USA
[54] and Europe [55] showed that even during low or no
vaccination uptake, natural variations in circulating genotypes
occurred with no association with the disease severity spec-
trum. In Belgium, increased prevalence of G2 genotypes was
observed after introduction of the RV1 vaccine despite a
reduction by 53% (season 2008/2009) of RV cases compared
with the pre-vaccination era (season 2005/2006) [56].
Furthermore, in Austria, where RV1 was the vaccine generally
used between 2010 and 2012, predominance of G2P[4] strains
was observed in children with breakthrough infection and in
samples from the general population despite a 64% reduction in
the overall RV associated hospitalization rate in 2011 compared
with the pre-vaccination era [21,57]. This ﬁnding is consistent
with a lower efﬁcacy shown in clinical trials of RV1 against
G2P[4] strains [30] and the emergence of G2P[4] in countries
or regions with high coverage of RV1 recipients such as
Germany [58], Brazil [59,60] or Australia [27]. However, a
case–control study in the USA showed a vaccine effectiveness
of RV1 against G2P[4] strains as high as 94% [61]. Similar
observations have been made for RV5; in regions in Australia
and the USA where RV5 was used, predominance of G3P[8]
was observed [27,62]. The predominance of G2P[4] or G3P[8]ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 735–743
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cannot be explained by vaccine pressure alone. Data from the
pre-vaccination era showed that large ﬂuctuations in circulating
serotypes are a natural phenomenon that has always occurred
in RV strains [50,63] and this should probably be taken into
account. However, as mentioned before, the relative redistri-
bution of the prevalence of serotypes in the remaining cases of
RVGE cannot be considered as a ‘substitution’ phenomenon
like in the cases of other vaccine preventable disease
(e.g. pneumococcus) and so far it is not affecting at all the
overall positive impact of RV vaccination.ConclusionThe high effectiveness of RV vaccinations has undoubtedly been
demonstrated in many countries and settings in both industri-
alized and resource deprived countries. A decrease of RV-
associated deaths has been demonstrated and the decreasing
numbers of severe cases and hospitalizations were detected not
only in target groups of RV vaccination, but also in age groups
that were not vaccinated, which is a sign of herd protection.
Sustained prolonged protection for longer than 3 years after
vaccination has been observed in countries with high vaccina-
tion coverage rates. Cost–beneﬁt analysis showed a favourable
pattern in both industrialized and resource-deprived countries
especially when indirect costs were considered and the cost of
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